Dr Reddy’s to Start Selling Generic Ozempic in India From March

Indian drugmaker Dr Reddy’s Laboratories Ltd. is planning to launch a generic version of Novo Nordisk A/S’s Ozempic in March after the drug’s patent expiry, becoming one of the first firms to capture ...
Yahoo Finance

Dr Reddy's Laboratories Ltd (RDY) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst ...

Revenue: INR8,727 crores (USD971 million), a growth of 4.4% year over year. EBITDA Margin: 23.5%, adjusted to 24.8% excluding a onetime provision. Gross Profit Margin: 53.6%, adjusted to 54.1% ...

Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories demonstrates low volatility in the market.

Welcome to the Dr Reddys Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock.

Dr Reddy's Laboratories gains 5% on posting Q3 results; brokerages divided

Dr Reddy's Laboratories share price jumps nearly 5% after Q3 results; revenue rises 4%, profit dips 14% YoY as brokerages stay mixed on outlook.
Nasdaq

Dr. Reddy’s Laboratories’ Credit Rating Reaffirmed by ICRA

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...

Dr. Reddy's Laboratories falls Monday, underperforms market

Dr. Reddy's Laboratories Ltd. closed 14.19% short of its 52-week high of 1,377.95 rupees, which the company reached on June ...

Dr. Reddy's Laboratories Faces Profit Contraction Amid Regional Divergence

Dr. Reddy’s Laboratories has released its financial results for the third quarter of fiscal year 2026. The pharmaceutical company reported a modest revenue increase but fell short of market ...
Seeking Alpha

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid ...

ANN ARBOR, Mich., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Dr. Reddy’s Laboratories, Inc. and its affiliate Dr.

Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2026 earnings call transcript

Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2026 Earnings Call Transcript January 21, 2026 Dr. Reddy’s Laboratories ...
Benzinga.com

Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business

On Thursday, Dr. Reddy's Laboratories Ltd (NYSE:RDY) stock is trading lower after the company released third-quarter 2025 earnings. The pharma company clocked a net income of $165 million, marginally ...
Benzinga.com

Dr Reddy's Laboratories Stock Dividends | NYSE:RDY | Benzinga

There are no upcoming dividends for Dr Reddy's Laboratories.The last dividend paid last dividend payout August 12, 2024 and was $0.48. Dr Reddy's Laboratories has no upcoming dividends reported. The ...
Business Wire

Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian Market

HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr ...